Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver Range Resources: A hidden gem in the mining industry (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Silo Pharma Inc SILO

Healthcare Biotechnology
Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and... see more

Recent & Breaking News (NDAQ:SILO)

Silo Pharma, Inc. Engages Donohoe Advisory to Assist with its Efforts to Obtain a Listing on a National Stock Exchange

GlobeNewswire December 14, 2021

Silo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide

GlobeNewswire December 2, 2021

Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods

GlobeNewswire November 18, 2021

Silo Pharma Reports Third Quarter Results and Operating Highlights

GlobeNewswire November 11, 2021

Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer's Disease

GlobeNewswire October 27, 2021

Silo Pharma achieves milestone - Partner Zylo Therapeutics Receive DEA Approval to Advance Silos time released Ketamine technology

GlobeNewswire October 7, 2021

Silo Pharma Advances Psychedelic Patent Portfolio

GlobeNewswire August 25, 2021

Silo Pharma Announces that JV partner Zylo Therapeutics Successfully Completes Initial Inspection for Ketamine Intradermal Research

GlobeNewswire August 11, 2021

Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent

GlobeNewswire July 27, 2021

Silo Pharma To Appear On National Media Broadcast on Psychedelics

GlobeNewswire July 21, 2021

Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore

GlobeNewswire July 12, 2021

Silo Pharma extends agreement for experimental Rheumatoid Arthritis nanoparticle homing peptide

GlobeNewswire July 7, 2021

Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson's and Bipolar Patients

GlobeNewswire June 8, 2021

Silo Pharma Submits Application for NASDAQ up-listing

GlobeNewswire May 25, 2021

Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson's disease has been submitted for ethics board review.

GlobeNewswire May 13, 2021

Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI's Z-pod(TM) technology for the transdermal time released delivery of therapeutics

GlobeNewswire April 28, 2021

Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ

GlobeNewswire April 22, 2021

Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology

GlobeNewswire April 7, 2021

Silo Pharma, Inc. Enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis

GlobeNewswire March 4, 2021

Silo Pharma to Present at Proactive's One2One Virtual Investor Forum

GlobeNewswire February 23, 2021